Last 218.90 INR
Change Today +2.70 / 1.25%
Volume 509.7K
SVLS On Other Exchanges
Symbol
Exchange
Natl India
As of 1:12 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

suven life sciences ltd (SVLS) Snapshot

Open
217.90
Previous Close
216.20
Day High
224.00
Day Low
216.00
52 Week High
11/3/14 - 236.70
52 Week Low
03/26/14 - 68.53
Market Cap
27.9B
Average Volume 10 Days
649.6K
EPS TTM
0.72
Shares Outstanding
127.3M
EX-Date
07/24/14
P/E TM
302.7x
Dividend
0.50
Dividend Yield
1.14%
Current Stock Chart for SUVEN LIFE SCIENCES LTD (SVLS)

Related News

No related news articles were found.

suven life sciences ltd (SVLS) Related Businessweek News

No Related Businessweek News Found

suven life sciences ltd (SVLS) Details

Suven Life Sciences Limited, a research-based biopharmaceutical company, designs, manufactures, and supplies bulk actives, drug intermediates, and fine chemicals for the life science industry worldwide. It provides advanced intermediates, intermediates, and active pharmaceutical ingredients. The company also offers contract research and manufacturing services, including development and supply of pharmaceutical and agro chemical intermediates for new chemical entities. In addition, it provides discovery and development of new chemical entities for CNS disorders; research collaborative projects with pharmaceutical companies; and drug discovery research services, including in-vitro screening and molecular biology, drug metabolism and pharmacokinetics, pharmacology, toxicology and genotoxicity, and bioanalysis, as well as operates a formulation development center. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. Suven Life Sciences Limited was founded in 1989 and is based in Hyderabad, India.

Founded in 1989

suven life sciences ltd (SVLS) Top Compensated Officers

Executive Chairman, Chief Executive Officer, ...
Total Annual Compensation: 12.0M
Wholetime Director, Member of Share Transfers...
Total Annual Compensation: 5.4M
Compensation as of Fiscal Year 2014.

suven life sciences ltd (SVLS) Key Developments

Suven Life Sciences Ltd Bags 3 Product Patents

Suven Life Sciences Ltd. has secured one product patent each from Eurasia, Japan and one from Mexico for its New Chemical Entities (NCEs). The granted claims of the patents include the class of selective 5-HT compounds discovered by the Hyderabad-based company and were being developed as therapeutic agents. With these new patents, Suven has 13 patents from Eurasia, 12 from Japan and 17 from Mexico.

Suven Life Sciences Limited Announces Unaudited Standalone Earnings Results for the Second Quarter and Six Months Ended September 30, 2014

Suven Life Sciences Limited announced unaudited standalone earnings results for the second quarter and six months ended September 30, 2014. For the quarter, the standalone company reported net sales of INR 1,414 million against INR 1,514.123 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 359.089 million against INR 691.930 million a year ago. Profit from ordinary activities before tax was INR 248 million against INR 455 million a year ago. Net profit was INR 248.365 million against INR 455.468 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 2.13 against INR 3.90 a year ago. Growth in revenue was INR 1,412 million against INR 1,515 million a year ago. Growth in EBIDTA was INR 398 million against INR 715 million a year ago. Lower revenue and PAT during this quarter compared to the same quarter last year is due to the absence of pre-launch supplies of intermediates for 3 of the NCE's which were done last year. For the six months, the standalone company reported net sales of INR 2,813.628 million against INR 2,600.819 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 914.019 million against INR 1,101.301 million a year ago. Profit from ordinary activities before tax was INR 841.265 million against INR 1,067.961 million a year ago. Net profit was INR 595.747 million against INR 753.187 million a year ago. Basic and diluted earnings per share before and after extraordinary items were INR 5.10 against INR 6.45 a year ago. Growth in revenue was INR 2,839 million against INR 2,633 million a year ago. Growth in EBIDTA was INR 988 million against INR 1,177 million a year ago. PAT reduced due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014.

Suven Life Sciences Limited, Q2 2015 Earnings Call, Nov 17, 2014

Suven Life Sciences Limited, Q2 2015 Earnings Call, Nov 17, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVLS:IN 218.90 INR +2.70

SVLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVLS.
View Industry Companies
 

Industry Analysis

SVLS

Industry Average

Valuation SVLS Industry Range
Price/Earnings 19.6x
Price/Sales 4.7x
Price/Book 7.9x
Price/Cash Flow 19.9x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUVEN LIFE SCIENCES LTD, please visit www.suven.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.